AAAAI & ACAAI GUIDELINES Bundle (free trial)

Primary Immunodeficiency

AAAAI & ACAAI GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/802140

Contents of this Issue

Navigation

Page 3 of 59

4 Internet resources for PIDDs URL Name/Description http://www.aaaai.org American Academy of Allerg y, Asthma & Immunolog y http://www.esid.org European Society for Immunodeficiencies http://www. immunodeficiencysearch.com Searchable database, clinical algorithms, laboratory resources http://www.info4pi.org Jeffrey Modell Foundation/Primary Immunodeficiency Resource Center http://www.ipidnet.org Immune Phenotyping in Primary Immunodeficiency http://www.ipopi.org International Patient Organization for Primary Immunodeficiencies http://www.primaryimmune.org Immune Deficiency Foundation http://web16.kazusa.or.jp/rapid/ Resource of Asian Primary Immunodeficiency Diseases (RAPID) http://www.usidnet.org US Immunodeficiency Network (USIDNET) Grading System for Recommendations Category of Evidence Strength of Recommendation Ia Evidence from meta-analysis of randomized controlled trials A Directly based on category I evidence Ib Evidence from at least one randomized controlled trial B Directly based on category II evidence or extrapolated recommendation from category I evidence IIa Evidence from at least one controlled study without randomization C Directly based on category III evidence or extrapolated recommendation from category I or II evidence IIb Evidence from at least one other type of quasiexperimental study D Directly based on category IV evidence or extrapolated recommendation from category I, II, or III evidence III Evidence from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case- control studies E Directly based on category LB evidence IV Evidence from expert committee reports or opinions or clinical experience of respected authorities, or both F Based on consensus of the Joint Task Force on Practice Parameters LB Evidence from laboratory-based studies under IV Category of Evidence

Articles in this issue

Links on this page

Archives of this issue

view archives of AAAAI & ACAAI GUIDELINES Bundle (free trial) - Primary Immunodeficiency